Head-to-head evidence
amycretin vs PEX168
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
amycretin
Developed by Novo Nordisk
NCT06542874 · Phase 2 · completed
This was a randomized, quadruple-blinded, placebo-controlled trial with 448 participants and a validated diabetes disease-control endpoint (HbA1c). The primary comparison was clearly positive, with HbA1c reductions of up to 1.8 percentage points (subcutaneous) and 1.5 points (oral) that were statistically significant against placebo.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2028 · NCT07400107 (registry estimate)
PEX168
Developed by Jiangsu Hengrui Pharmaceuticals and partners
NCT02477969 · Phase 3 · status unknown
This was a randomized, triple-blind, placebo-controlled trial with 587 participants, testing PEX168 against placebo, both added to metformin, using change in HbA1c as the primary measure. A published report of the trial's results describes the primary endpoint as met, with substantially more PEX168 patients than placebo patients reaching HbA1c targets at 24 weeks.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: amycretin's landscape · PEX168's landscape